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Abstract
Diabetes plays an important role in the complex relationship between chronic kidney dis-
ease (CKD) and cardiovascular disease. This retrospective observational study compared
the influence of estimated glomerular filtration rate (eGFR) and proteinuria on the risk of
major adverse cardiovascular event (MACE; myocardial infarction or stroke) in CKD patients
with and without diabetes. Data were from a linked database of UK electronic health rec-
ords. Individuals with CKD and no prior MACE were classified as type 1 diabetes (T1DM; n
= 164), type 2 diabetes (T2DM; n = 9,711), and non-diabetes (non-DM; n = 75,789). Monthly
updated time-dependent Cox proportional hazard models were constructed to calculate
adjusted hazard ratios (aHRs) for progression to MACE from first record of abnormal eGFR
or proteinuria (index date). In non-DM, aHRs (95% CIs) by baseline eGFR category (refer-
ent G2) were G1: 0.70 (0.55–0.90), G3a: 1.28 (1.20–1.35), G3b: 1.64 (1.52–1.76), G4: 2.19
(1.98–2.43), and G5: 3.12 (2.44–3.99), and by proteinuria category (referent A1) were A2:
1.13 (1.00–1.28), A2/3 (severity indeterminable): 1.58 (1.28–1.95), and A3: 1.64 (1.38–
1.95). In T2DM, aHRs were G1: 0.98 (0.72–1.32), G3a: 1.18 (1.03–1.34), G3b: 1.31 (1.12–
1.54), G4: 1.87 (1.53–2.29), G5: 2.87 (1.82–4.52), A2: 1.22 (1.04–1.42), A2/3: 1.45 (1.17–
1.79), and A3: 1.82 (1.53–2.16). Low numbers in T1DM precluded analysis. Modelling
T2DM and non-DM together, aHRs were, respectively, G1: 3.23 (2.38–4.40) and 0.70
(0.55–0.89); G2: 3.18 (2.73–3.70) and 1.00 (referent); G3a: 3.65 (3.13–4.25) and 1.28
(1.21–1.36); G3b: 4.01 (3.40–4.74) and 1.65 (1.54–1.77); G4: 5.78 (4.70–7.10) and 2.21
(2.00–2.45); G5: 9.00 (5.71–14.18) and 3.14 (2.46–4.00). In conclusion, reduced eGFR and
proteinuria were independently associated with increased risk of MACE regardless of diabe-
tes status. However, the risk of MACE in the same eGFR state was 4.6–2.4 times higher in
T2DM than in non-DM.
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Introduction
It has been estimated that 11–13% of the global population has some degree of chronic kidney
disease (CKD),[1] as defined by international criteria based on structural damage and reduced
function.[2,3]
A complex relationship exists between CKD and cardiovascular (CV) disease (CVD), with
each being an established risk factor for the other.[4] CKD is an important risk factor for a
wide variety of CVDs, including coronary heart disease and stroke,[5,6] even after accounting
for the increased prevalence of traditional cardiometabolic risk factors in people with CKD.
There is evidence that CV risk is increased at even the mildest levels of microalbuminuria,[7]
and it is apparent that individuals with CKD are more likely to die of CVD than to progress to
end stage renal disease.[8]
Glucose metabolism is integral to the pathophysiology of both diseases. Diabetes is the lead-
ing cause of CKD in all developed and most developing countries,[9] with approximately 20%
of people with type 2 diabetes showing evidence of diabetic nephropathy within 20 years of
diabetes onset,[10] and diabetes itself being an independent risk factor for CVD.[11] Whilst
there is a J- or U-shaped association between hyperglycaemia—as measured by glycosylated
haemoglobin (HbA1c)—and cardiovascular events,[12] the association between HbA1c and
CKD risk is essentially a direct, linear association.[13]
With the current prevalence of diabetes estimated to be 9.4% of the adult population in the
USA and 4.5% of the total population in the UK and the worldwide prevalence estimated to
increase to 7.7% by 2030,[14–16] the public health impact of this triad of diseases is severe and
increasing, accelerated by ageing populations and the rising prevalence of obesity and
inactivity.
The purpose of this study, using a large linked data set of UK electronic health records, was
to characterize the risk of and hospitalization rates for major adverse cardiovascular events
(MACE), here defined as myocardial infarction or stroke, in a CKD population. In particular,
this study compared the independent influences on this risk of two key aspects of kidney mor-
bidity: decreased function as measured by estimated glomerular filtration rate (eGFR) and
structural damage as evidenced by proteinuria, in people with and without diabetes.
Methods
Study design and data sources
This was a retrospective cohort study using primary care data from the UK Clinical Practice
Research Datalink (CPRD) and linked inpatient data from the Hospital Episode Statistics
(HES) for England.[17,18]
CPRD is an ongoing database of pseudonymized data collected in a non-interventional way
from participating primary care practices throughout the UK. At July 2015, it contained
research-quality electronic health records for more than 13 million patients registered at 689
practices. Data include demographics, diagnoses, symptoms, investigation and test results,
referrals, and prescriptions. The records of more than 7 million CPRD patients (54%) regis-
tered with participating English practices can be linked, via a trusted third party, with other
data sources, notably secondary care data from HES.
Clinical diagnoses, symptoms, and procedures in CPRD primary care data are recorded by
Read Code (Version 2), a standard clinical terminology system used in UK general practice.
[19] In HES data, diagnoses are encoded according to the 10th revision of the International
Classification of Disease (ICD-10),[20] and procedures according to the UK Office of Popula-
tion Censuses and Surveys Classification of Interventions and Procedures, version 4 (OPCS-
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4).[21] A number of studies have validated Read code recording in CPRD and its predecessor,
the General Practice Research Database, showing a high positive predictive value overall.[22]
CPRD patients are representative of the UK population in terms of age, gender, and ethnicity,
and patients eligible for linkage to HES are in turn representative of the CPRD population.
[17,23]
Ethics
All patient data for the study were de-identified at source and then fully anonymized by a
trusted third party on behalf of the CPRD before being made available to the researchers. Indi-
vidual patients can opt out of contributing data to the CPRD. Approval for this study was
granted by the CPRD Independent Scientific Advisory Committee (reference number
17_191R).
Study population
The study population was drawn from patient records and practices classed by CPRD as being
of an acceptable research quality and eligible for linkage to the HES data set. Individuals were
selected if they had at least one diagnosis of chronic kidney disease (CKD) recorded in CPRD
or HES and at least two abnormal eGFR measurements (<90 ml/min/1.73m2, indicative of
decreased function; S1 Table) recorded between 91 and 730 days apart, adopting criteria used
in the study by Schneider and colleagues.[24] The study index date was set as the earlier of the
patient’s first abnormal eGFR record or, if available, first abnormal (increased) microalbumi-
nuria or proteinuria record (as described in S2 Table). Individuals were required to have been
registered at the practice for at least 365 days at index date and to have no prior record of dialy-
sis, kidney transplant, renal cancer, myocardial infarction, or stroke.
Glomerular filtration rate values were estimated from serum creatinine test results by
means of the CKD Epidemiology Collaboration (CKD-EPI) equation,[25] incorporating its
adjustment for black ethnicity where this could be identified from the data source.
Tests for microalbuminuria and proteinuria (collectively termed proteinuria hereafter) are
recorded in the CPRD primary care data in five different structured data areas (SDAs), three
of which: ‘albumin–creatinine ratio’, ‘urine microalbumin’, and ‘urine biochemistry’ record
both quantitative and qualitative results, while another two: ‘urinalysis—protein’ and ‘urine
dipstick for protein’ record qualitative results only. Test data are accompanied by Read codes,
which may provide more information about the nature of the test or of its result, and by data
qualifiers (such as ‘normal’, ‘negative’, ‘+++’).
To address the challenge of identifying specific measures of proteinuria with appropriate
units of measurement from the three quantitative SDAs, we extended the approach of Liang
and colleagues by classifying each test SDA, unit of measurement, and accompanying Read
code as specific, non-specific, or conflicting with respect to each of these measures in turn:
albumin–creatinine ratio, protein–creatinine ratio, albumin excretion rate, protein excretion
rate, spot albumin and spot protein.[26] Records were selected if at least one dimension was
specific for a measure, with no conflicting dimension. Exceptions to this rule were: 1) where
the Read code dimension was conflicting but the unit was specific; and 2) for spot albumin,
where the title of the SDA was conflicting (‘albumin–creatinine ratio’) but the unit of measure-
ment was specific.
Qualitative results were identified from the qualitative test SDAs and also from quantitative
records that did not meet any of the rules listed above or had no numeric result entered. In
addition, clinical records from CPRD and HES were included as qualitative results if their
respective Read or ICD-10 codes indicated the absence or presence of proteinuria.
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In accordance with the Kidney Disease: Improving Global Outcomes (KDIGO) clinical
practice guidelines,[3] the severity of chronic kidney disease was classified into six categories,
from G1: normal or high to G5: kidney failure, based on the person’s eGFR measurements (S1
Table). Classification of proteinuria severity was also based on a KDIGO classification,[3]
from A1: normal to mildly increased to A3: severely increased, with a fourth category, A2/3,
added here to encompass qualitative results from which the severity of abnormality could not
be determined (S2 Table).
The selected individuals were classified into three cohorts: type 1 diabetes (T1DM), type 2
diabetes (T2DM), and non-diabetes (non-DM). Individuals were entered in the T2DM cohort
if they had one or more diagnostic record for type 2 diabetes or one or more prescription for a
glucose-lowering drug other than insulin, and had no record of secondary diabetes nor, if
identified by metformin prescription alone, of polycystic ovarian syndrome. Individuals were
entered in the T1DM cohort if they had one or more prescription for insulin but none for any
other glucose-lowering drug, had no diagnoses of type 2 diabetes, and at least one of the fol-
lowing criteria applied:
• At least one diagnostic record of type 1 diabetes using a diagnostic code other than a Read
code for ‘insulin-dependent diabetes mellitus’ (a term that may be misapplied to a person
with type 2 diabetes receiving insulin therapy)
• At least one diagnostic record of type 1 diabetes and aged 30 years or younger at diabetes
presentation (earlier of first insulin or first diagnosis)
• At least one diagnostic record of type 1 diabetes, aged 31 to 39 at diabetes presentation, and
a body mass index (BMI) at presentation� 25 kgm-2.
Individuals were entered in the non-DM cohort if they had no record of diabetes or glu-
cose-lowering therapy in the data source and had no more than one record of HbA1c� 6.5%
(47.5 mmol/mol).
Individuals in the two diabetes cohorts were required to have a diabetes presentation date
on or before their index date. Individuals in the T2DM and non-DM cohorts were required to
be aged 40 years or older at index date; those in the T1DM cohort were required to be 25 years
or older at index.
End of data follow-up was calculated as the earliest of: the person’s death or transfer-out
date, their practice’s last data-collection date, their individual HES linkage date, or the end of
the linkage scheme (31 March 2014). Data censoring was also invoked at a person’s first
record, post index date, of dialysis, renal transplant, or renal cancer.
Study endpoints
The endpoints of this study were calculated by diabetes cohort and comprised:
• Unadjusted time to first MACE, stratified by eGFR and proteinuria category
• Adjusted risk of first MACE by eGFR and proteinuria category
• Event rates for hospital admissions for MACE
The composite outcome of first MACE was identified as the individual’s first record from
primary care or HES inpatient data having a diagnostic code for myocardial infarction or
stroke. Hospitalizations for MACE were identified from HES inpatient data as distinct admis-
sions having a diagnosis of myocardial infarction or stroke.
The outcomes of dialysis and transplant were determined by Read code in CPRD or by
ICD-10 or OPCS-4 procedural code in HES inpatient data. Baseline values for BMI, weight,
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height, systolic and diastolic blood pressure, serum creatinine, and—for the diabetes cohorts—
HbA1c were identified from the nearest record to index date, provided this was no more than
365 days before or 30 days after index date and searching in the following order: -30 days, +30
days, -365 days. Baseline smoking and alcohol status were identified from the nearest record
prior to index date; if no such status was recorded, the nearest status following index date was
used.
Statistical methods
Baseline characteristics for each of the three cohorts: non-DM, T1DM, and T2DM were sum-
marized using mean and standard deviation or median and interquartile range, depending on
their distribution.
For each cohort and for an ‘overall’ cohort combining all T1DM, T2DM, and non-DM
individuals, Kaplan–Meier curves for unadjusted times to first MACE were produced, strati-
fied by baseline eGFR and by proteinuria category at or nearest to MACE (proteinuria at base-
line was too sparse to enable stratification by these values).
Cox proportional hazard models were then applied to the individual and combined cohorts
to estimate the adjusted hazard ratios (aHR) for first MACE, with 95% confidence intervals
(CI). In these time-dependent models, eGFR and proteinuria levels were updated on a
monthly basis, applying last-observation-carried-forward (preferred) or next-observation-car-
ried-backward techniques where necessary and where, in the case of proteinuria, a patient had
�1 proteinuria measurement (all patients had�2 eGFR measurements). The parameterization
of each covariate is outlined in Table 1.
In the first set, models were applied to three cohorts: T2DM, non-DM, and the overall
cohort (including T1DM), adjusting for the separate effects of eGFR category (compared with
the referent category G2), proteinuria category (referent A1), and the potential confounding
covariates of baseline age at the index date, gender, baseline BMI, baseline blood pressure,
smoking status, index year, immunosuppression status, and prior comorbidities. Additionally,
in the T2DM cohort, the model was adjusted for baseline HbA1c and, in the overall cohort, for
baseline HbA1c and diabetes cohort membership. Separate analyses for the T1DM cohort
were not carried out because of small numbers. G2 was chosen as the referent category for the
eGFR analyses because of small numbers in the G1 category.
The second set of models was applied to the T2DM and non-DM cohorts together to con-
sider how eGFR category affected the risk of MACE between these two larger cohorts.
Adjusted hazard ratios for time to first MACE were presented by diabetes status and eGFR
group, with the G2 group in non-DM individuals as the referent and adjusting for the poten-
tially confounding covariates listed above. As a post-hoc analysis, we considered the results for
non-DM and T2DM separately by gender.
The third set of models considered the effects of eGFR and proteinuria interaction on the
risk of MACE in the combined T1DM, T2DM, and non-DM cohort. The G1 eGFR category in
combination with the A1 proteinuria category was used as the referent, and models were addi-
tionally adjusted for gender, cohort, and baseline age, smoking status, and blood pressure.
Event rates for hospitalizations for MACE were calculated per 1,000 person years (PKPY)
follow-up (to censor date).
Results
Baseline characteristics
There were 75,789 people in the non-DM cohort, 9,711 in the T2DM, and 164 in the T1DM.
Table 1 details the baseline characteristics for each cohort. Individuals in the non-DM cohort
Cardiovascular events in chronic kidney disease by disease severity and diabetes status
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had the highest mean age (69.2 years), followed by those in the T2DM cohort (66.6 years) and
then the T1DM cohort (46.5 years). The non-DM cohort was 38.2% male, the T2DM cohort
51.0% male, and the T1DM cohort 57.9% male. The median duration of diagnosed diabetes at
Table 1. Baseline characteristics for the type 1 diabetes (T1DM), type 2 diabetes (T2DM) and non-diabetes (non-DM) cohorts.
Characteristic Non-DM T2DM T1DM Overall
N (%) 75,789 (88.5) 9,711 (11.3) 164 (0.2) 85,664 (100)
Age, years, mean (sd) 69.2 (11.3) 66.6 (10.4) 46.5 (13.0) 68.8 (11.3)
Male, n (%) 28,985 (38.2) 4,950 (51.0) 95 (57.9) 34,030 (39.7)
Duration of diagnosed diabetes, years, median (IQR) — (—) 3.1 (0.7–8.4) 20.1 (14.0–30.4) 3.2 (0.8–8.7)
Duration of diagnosed CKD, years, median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
Duration of diagnosed renal disease, years, median (IQR) 4.3 (2.2–6.7) 4.8 (2.8–7.1) 3.3 (0.1–5.8) 4.4 (2.3–6.7)
BMI, kgm-2, mean (sd) 27.6 (5.1) 30.1 (6.0) 25.8 (3.9) 28.1 (5.4)
Weight, kg, mean (sd) 75.9 (16.2) 84.4 (18.6) 76.8 (13.3) 77.8 (17.1)
Height, m, mean (sd) 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) 1.7 (0.1)
Systolic BP, mmHg, mean (sd) 149.3 (21.3) 146.9 (19.8) 139.2 (20.9) 149.0 (21.1)
Diastolic BP, mmHg, mean (sd) 83.8 (11.6) 81.5 (10.8) 78.9 (11.5) 83.5 (11.5)
Smoking, n (%)
Never 43,702 (57.7) 5,231 (53.9) 90 (54.9) 49,023 (57.2)
Prior smoker 19,385 (25.6) 2,748 (28.3) 28 (17.1) 22,161 (25.9)
Current smoker 12,125 (16) 1,701 (17.5) 45 (27.4) 13,871 (16.2)
Missing 577 (0.8) 31 (0.3) 1 (0.6) 609 (0.7)
Alcohol, n (%)
Never 14,449 (19.1) 2,412 (24.8) 23 (14.0) 16,884 (19.7)
Prior drinker 1,376 (1.8) 277 (2.9) 6 (3.7) 1,659 (1.9)
Current drinker 55,086 (72.7) 6,624 (68.2) 123 (75) 61,833 (72.2)
Missing 4,878 (6.4) 398 (4.1) 12 (7.3) 5,288 (6.2)
HbA1c, %, median (IQR) 5.7 (5.4–6.0) 7.6 (6.6–9.0) 9.0 (8.0–10.5) 7.4 (6.3–8.9)
HbA1c, mmol/mol, median (IQR) 38.8 (35–42) 59 (49–75) 75 (64–91) 57 (45–74)
Serum creatinine, μmol/l, mean (SD) 103.7 (31.5) 99.2 (28.2) 116.2 (60.7) 103.2 (31.3)
GP contacts in prior year, n, median (IQR) 5 (3–9) 8 (4–14) 7 (3–12) 5 (3–9)
History of peripheral vascular disease, n (%) 628 (0.8) 336 (3.5) 12 (7.3) 976 (1.1)
eGFR category, n (%)�
G2 38,892 (51.3%) 6,003 (61.8%) 92 (56.1%) 44,987 (52.5%)
G3a 26,599 (35.1%) 2,193 (22.6%) 14 (8.5%) 28,806 (33.6%)
G3b 8,203 (10.8%) 731 (7.5%) 12 (7.3%) 8,946 (10.4%)
G4 1,657 (2.2%) 175 (1.8%) 10 (6.1%) 1,842 (2.2%)
G5 248 (0.3%) 16 (0.2%) 2 (1.2%) 266 (0.3%)
Missing 190 (0.3%) 593 (6.1%) 34 (20.7%) 817 (1.0%)
Proteinuria category, n (%)��
A1 23,650 (31.2%) 4,325 (44.5%) 57 (34.8%) 28,032 (32.7%)
A2 7,319 (9.7%) 2,335 (24.0%) 29 (17.7%) 9,683 (11.3%)
A2/3 453 (0.6%) 303 (3.1%) 7 (4.2%) 762 (0.9%)
A4 1,721 (2.3%) 1,121 (11.5%) 40 (24.4%) 2,882 (3.4%)
Missing 42,647 (56.3%) 1,627 (16.8%) 31 (18.9%) 44,305 (51.7%)
IQR, interquartile range; BMI, body mass index; BP, blood pressure; HbA1c, glycosylated haemoglobin
� At baseline
�� Based on nearest record prior to earlier of first major adverse cardiovascular event or data censoring
https://doi.org/10.1371/journal.pone.0221044.t001
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index date was higher in T1DM (20.1 years) than in T2DM (3.1 years), which was to be
expected. Median duration of diagnosed renal disease was highest in T2DM (4.8 years) and
lowest in T1DM (3.3 years). BMI was lowest in T1DM (25.8 kg/m2) and highest in T2DM
(30.1 kg/m2). The proportion of prior (ex-) smokers was highest in T2DM (28.3%) and lowest
in T1DM (17.1%), although the T1DM cohort had the highest proportion of current smokers
(27.4%). Median HbA1c was higher in the T1DM cohort, at 9.0% (75 mmol/mol), than in the
T2DM cohort, where it was 7.6% (59 mmol/mol). Understandably, there was marked variabil-
ity between the cohorts.
Unadjusted time to first major adverse cardiovascular event
Kaplan–Meier curves showing the time to first MACE event for each cohort, stratified sepa-
rately by eGFR and proteinuria categories, are illustrated in Figs 1 and 2, respectively.
The T1DM cohort comprised only a small number of people, and therefore its Kaplan–
Meier curves are difficult to interpret.
When the T2DM cohort was stratified by eGFR category, <50% of people experienced an
event within the follow-up period in all categories; therefore, the median could not be calcu-
lated. The upper quartile of survival was reached in G2 (15.1 years, 95%CI 14.2–NA), G3a
(11.6, 11.1–13.1), G3b (9.0, 8.1–14.8), and G4 (6.9, 4.6–8.9) (Fig 1B). When this cohort was
stratified by proteinuria category, the upper quartile of survival was reached in A1 (15.5, 15.4–
NA), A2 (14.8, 13.8–NA), A2/3 (10.7, 11.3–14.1), and A3 (12.9, 11.3–14.1) (Fig 2B).
There was a discernible difference between eGFR categories in non-DM (Fig 1C). The
upper quartiles of survival were 12.0 years (95%CI 11.3–12.6) in category G3b, 9.4 (8.2–NA) in
G4, and the upper quartiles of survival were not reached for those with a measurement in G5.
There was a clear distinction between proteinuria categories after eight years (Fig 2C). People
in proteinuria categories A2/3 and A3 (who shared a similar pattern) progressed to MACE at
the most rapid rate, followed by those in category A2 and then A1.
In the overall cohort, comprising all three cohorts together, and stratifying by eGFR cate-
gory, the upper quartile of survival was 15.6 years for G3a (95%CI 15.2– NA), 11.7 (11.0–12.4)
for G3b, 8.9 (7.9–10.9) for G4, and was not reached for G5 (Fig 1D). When the merged cohorts
were stratified by proteinuria category, the upper quartile of survival was reached in A2/3 (14.7
years, 12.3–NA) and A3 (14.1, 13.6–NA) (Fig 2D).
Across all cohorts, patients in the ‘missing’ proteinuria category progressed more rapidly to
MACE than did patients with known proteinuria status.
Adjusted risk of progression to first major adverse cardiovascular event
Applying Cox proportional hazards models to the merged cohorts (T1DM, T2DM, and non-
DM) revealed a significant difference in adjusted MACE risk between eGFR category G1 and
the referent G2 (adjusted hazard ratio (aHR) = 0.82, 95%CI 0.68–0.99) (Fig 3). All other eGFR
categories showed an increased risk of MACE compared with G2: people in category G3a had
an aHR of 1.26 (1.19–1.33); in G3b, this was 1.58 (1.48–1.68); in G4, 2.12 (1.94–2.33); and in
G5, 3.10 (2.50–3.84). There were also differences in adjusted MACE rates between proteinuria
category A2 (aHR = 1.15, 95%CI 1.05–1.27), A2/3 (1.48, 1.28–1.72), and A3 (1.71, 1.52–1.93)
by comparison with the referent A1 (Fig 3). Prior coronary heart disease (1.42, 1.34–1.51),
hypertension (1.09, 1.04–1.14), and cerebrovascular disease (1.36, 1.24–1.48) resulted in an
increased aHR. Ex-smokers and current smokers had an increased risk of MACE of 10% (1.10,
1.05–1.16) and 53% (1.53, 1.45–1.62), respectively. BMI was not significant in the model. Peo-
ple with severe blood pressure has the highest risk of MACE when compare with non-hyper-
tension (1.25, 1.12–1.39), followed by stage 2 (1.16, 1.08–1.25) and then stage 1 hypertension
Cardiovascular events in chronic kidney disease by disease severity and diabetes status
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(1.12, 1.06–1.19). By comparison with the non-DM cohort, people in T2DM had an increased
risk of MACE (2.82, 2.49–3.19). Males had an increased risk of MACE compared with females.
Adjusted risk of progression to first major adverse cardiovascular event by
diabetes status
Separate models were repeated for the T2DM and non-DM cohorts. (The proposed models
were inappropriate for the T1DM cohort because of the low cohort membership.) Within
T2DM, there was no significant difference between eGFR category G1 (aHR = 0.98, 95%CI
0.72–1.32) compared with the referent G2 (Fig 3). There was an association between
Fig 1. Kaplan–Meier plots, with 95% confidence intervals, for time to first major adverse cardiovascular event by diabetes cohort and baseline eGFR
category. a. Type 1 diabetes, b. Type 2 diabetes, c. Non-diabetes, d. Overall MACE, major adverse cardiovascular event. eGFR, estimated glomerular
filtration rate. � Index date defined as the earlier of the patient’s first abnormal eGFR or, if available, first abnormal proteinuria record.
https://doi.org/10.1371/journal.pone.0221044.g001
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worsening eGFR and MACE rates in categories G3a (1.18, 1.03–1.34), G3b (1.31, 1.12–1.54),
G4 (1.87, 1.53–2.29), and G5 (2.87, 1.82–4.52) compared with G2.
A similar pattern of association was seen in the results from the non-DM cohort (Fig 3),
where adjusted rates were higher in eGFR category G3a (aHR = 1.28, 95%CI 1.20–1.35), G3b
(1.64, 1.52–1.76), G4 (2.19, 1.98–2.43), and G5 (3.12, 2.44–3.99) compared with the referent
G2. The only difference was the G1 category, where there was a greater reduction in risk of
MACE compared with G2 than in the T2DM cohort (0.70, 0.55–0.90) (Fig 3).
Within the T2DM cohort, differences in adjusted risk between the various proteinuria cate-
gories were significant: A2 (aHR = 1.22, 95%CI 1.04–1.42), A2/3 (1.45, 1.17–1.79), and A3
(1.82, 1.53–2.16) compared with the referent A1. A similar pattern was seen in the non-DM
Fig 2. Kaplan–Meier plots, with 95% confidence intervals, for time to first major adverse cardiovascular event by diabetes cohort and nearest
proteinuria category prior to event. a. Type 1 diabetes, b. Type 2 diabetes, c. Non-diabetes, d. Overall MACE, major adverse cardiovascular event. � Index
date defined as the earlier of the patient’s first abnormal eGFR or, if available, first abnormal proteinuria record.
https://doi.org/10.1371/journal.pone.0221044.g002
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cohort: A2 (1.13, 1.00–1.28), A2/3 (1.58, 1.28–1.95), and A3 (1.64, 1.38–1.95) compared with
A1 (Fig 3). Adjusted hazard ratios for the other covariates are detailed.
In a second set of models adjusting by eGFR category and diabetes status in the combined
T2DM and non-DM cohorts, with the G2 category in non-DM as the referent, there was an
increase in aHRs within each diabetes cohort as the eGFR category increased (Fig 4). All eGFR
categories in the T2DM cohort had a significantly higher aHR than did the corresponding
eGFR category in the non-DM cohort: G1: 3.23 (95% CI 2.38–4.40) versus 0.70 (0.55–0.89) in
non-DM (ratio 4.6); G2: 3.18 (2.73–3.70) versus 1.00 (referent; ratio 3.2); G3a: 3.65 (3.13–4.25)
versus 1.28 (1.21–1.36; ratio: 2.9); G3b: 4.01 (3.40–4.74) versus 1.65 (1.54–1.77; ratio: 2.4); G4:
5.78 (4.70–7.10) versus 2.21 (2.00–2.45; ratio: 2.6); and G5: 9.00 (5.71–14.18) versus 3.14
(2.46–4.00; ratio: 2.9), respectively.
A post-hoc analysis considered the effect that gender had on MACE risk. There was a simi-
lar trend observed amongst both males and females in each cohort for eGFR severity categories
G1 to G4, inclusive (Fig 5). However, there was a differing pattern in the G5 category, whereby
Fig 3. Adjusted hazard ratios for first major adverse cardiovascular event in type 2 diabetes, non-diabetes, and overall (combined types 1 and 2 diabetes and
non-diabetes) cohorts. � Non-hypertension = systolic< 140, or diastolic< 90; stage 1 = 140� systolic blood pressure< 160, or 90� diastolic< 100; stage
2 = 160� systolic< 180, or 100� diastolic< 110; severe = systolic� 180, or diastolic� 110 (units = mmHg). �� Patient has a prior record of immunosuppressive
disease or was prescribed an immunosuppressive therapy in the year prior to baseline. aHR, adjusted hazard ratio. CI, confidence interval. DM, diabetes. Non-DM, non-
diabetes. T2DM, type 2 diabetes. ACE, angiotensin-converting enzyme inhibitor. ARB, angiotensin II receptor antagonist. HbA1c, glycosylated haemoglobin.
https://doi.org/10.1371/journal.pone.0221044.g003
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in the T2DM cohort, females had an increased risk of MACE with an aHR of 4.51 (95% CI
2.54–8.01) vs. males who had an aHR of 1.58 (0.73–3.46). A similar pattern was seen in the
non-DM cohort, where females had an aHR of 3.81 (2.80–5.18) vs. males, who had an aHR of
2.42 (1.63–3.6).
Fig 4. Adjusted hazard ratios for first major adverse cardiovascular event by eGFR category and diabetes status in Cox models combining
type 2 and non-diabetes cohorts. eGFR, estimated glomerular filtration rate. aHR, adjusted hazard ratio. CI, confidence interval. Non-DM, non-
diabetes. T2DM, type 2 diabetes. aHR, adjusted hazard ratio.
https://doi.org/10.1371/journal.pone.0221044.g004
Fig 5. Adjusted hazard ratios for first major adverse cardiovascular event by time-dependent eGFR category in Cox models for type 2 and non-diabetes
cohorts split by gender. a. Non-diabetes–female, b. Non-diabetes–male, c. Type 2 diabetes–female, d. Type 2 diabetes–male eGFR, estimated glomerular
filtration rate. aHR, adjusted hazard ratio. CI, confidence interval. Non-DM, non-diabetes. T2DM, type 2 diabetes.
https://doi.org/10.1371/journal.pone.0221044.g005
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Adjusted risk of progression to first major adverse cardiovascular event by combined
eGFR and proteinuria status. There was a consistent pattern when models were applied
adjusting for the interaction between eGFR and proteinuria in the overall cohort (Fig 6). All
G5 combinations with any proteinuria status (including the normal level A1) showed very
high risk of MACE (aHR>3.5), with people combining G5/A1, G5/A2, and G5/A3 having
aHRs of 10.93 (95% CI 4.58–26.10), 4.70 (1.95–11.35), and 5.23 (2.74–9.97), respectively.
Adjusted risk of MACE was also very high in the combination G4/A3 (4.19, 2.58–6.8) and
high (2.5<aHR�3.5) in G4/A1 (2.78, 1.72–4.5), G4/A2, (2.62, 1.60–4.30), and G3b/A3 2.53
(1.57–4.06). There was a moderately increased adjusted risk (1.5<aHR�2.5) of progressing to
MACE in all other combinations of proteinuria status with G3b: G3b/A1 (1.62, 1.04–2.53) and
G3b/A2 (1.69, 1.07–2.66) and in all other eGFR combinations with severe proteinuria A3: A3/
G1 (1.60, 0.68–3.76), A3/G2 (1.59, 0.98–2.60), and A3/G3a (1.63, 1.00–2.65).
Hospitalization rates for major adverse cardiovascular events
Rates of hospitalization for MACE were higher in T2DM, at 18.4 admissions per 1,000 person
years (PKPY), than in non-DM (13.5 PKPY) and T1DM (6.1 PKPY) (Table 2). When people
in non-DM were stratified by eGFR category at baseline, the crude event rates were highest in
G5 (kidney failure; 32.4 PKPY) followed by G4 (27.3 PKPY), G3b (21.0 PKPY), G3a (14.4
PKPY), and G2 (11.2 PKPY). A similar pattern was seen in T2DM, where the crude event rates
were highest in G4 (43.8 PKPY) followed by G3b (28.7 PKPY), G3a (21.1 PKPY), and G2 (15.9
PKPY). There were low numbers of events in the T1DM cohort and the G5 categories, there-
fore, the crude rates should be interpreted with care. When stratified by proteinuria, people
with a proteinuria category of A2/3 (increased) and A3 (severely increased) had similar rates
of admissions in non-DM (10.4 vs. 9.1 PKPY, respectively) and in T2DM (20.2 vs. 18.5 PKPY,
respectively).
People with a proteinuria category of A2 (moderately increased) had a crude rate of 6.0
PKPY in non-DM and 14.3 PKPY in T2DM. People with a proteinuria category of A1 (normal
to mildly increased) had a crude rate of 4.3 PKPY in non-DM and 12.4 PKPY in T2DM
(Table 2).
Discussion
This study characterized the influence of eGFR and proteinuria, two commonly used metrics
of renal disease morbidity, on the risk of progression to major adverse cardiovascular event
(MACE) and found both to be directly and independently associated with increased risk. This
was evident both in non-diabetes and in type 2 diabetes, with insufficient follow-up in people
with type 1 diabetes. However, the adjusted risk of progression to MACE in the same eGFR
category was between 4.6 and 2.4 times higher in those with type 2 diabetes than in those with
no diabetes, depending upon where the comparison was made, with this ratio decreasing over-
all as renal function declined.
The patterns of risk change by eGFR category followed a similar pattern in both the type 2
diabetes and non-diabetes cohorts, with aHRs increasing as eGFR function decreased from G2
to G5. It appeared, in crude analysis, that the type 1 cohort had a higher risk of MACE at eGFR
category G5 (kidney failure) than did the type 2 diabetes cohort, but the type 2 diabetes cohort
had a higher overall risk of MACE than did the type 1 diabetes cohort, which may reflect the
former’s higher mean age, BMI, and duration of diabetes. This increased risk of MACE as
eGFR function decreases is similar to findings by Kottgen and colleagues,[27] where the
adjusted risk of heart failure was 76% higher in persons with moderately or severely decreased
kidney function (categories G3a–G5) compared with those with mildly decreased function
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(category G2). A post-hoc analysis by gender showed that the pattern of increased risk of
MACE by eGFR severity differed between females and males; however, further research is
needed to understand the factors potentially increasing risk in women with kidney failure.
Increased severity of proteinuria was also independently associated in this study with
increased adjusted risk of progression to MACE in both the type 2 diabetes and non-diabetes
Fig 6. Adjusted hazard ratios for first major adverse cardiovascular event by combined eGFR and proteinuria categories in Cox models combining type
1, type 2, and non-diabetes cohorts. Low risk: adjusted hazard ratio (aHR) 1–1.5, moderately increased risk: aHR 1.5–2.5, high risk: aHR 2.51–3.5, very high
risk: aHR>3.5; 95% confidence intervals are shown in parentheses. N, number of patient months.
https://doi.org/10.1371/journal.pone.0221044.g006
Table 2. Hospital admission rates for MACE by eGFR category at baseline and by proteinuria category nearest to admission date, by diabetes cohort.
Non-DM T1DM T2DM Overall
n Rate PKPY n Rate PKPY n Rate PKPY n Rate PKPY
eGFR category at baseline
G1
G2 3,480 11.2 7 9 841 15.9 2,607 28.4
G3a 2,888 14.4 0 0 370 21.1 3,881 41.8
G3b 1,125 21.0 0 0 142 28.7 2,201 51.9
G4 219 27.3 0 0 37 43.8 506 82.6
G5 29 32.4 0 0 0 0 28 49.2
Overall 7,763 13.5 8 6.1 1,485 18.4 9,256 39.3
Proteinuria category nearest MACE admission date
A1 939 4.3 1 1.8 485 12.4 1,425 18.6
A2 396 6.0 1 4.1 302 14.3 699 24.3
A2/3 40 10.4 0 0.0 49 20.2 89 30.6
A3 132 9.1 2 6.4 179 18.5 313 34.0
Missing 6,256 22.9 4 24.5 470 55.0 6,730 102.5
Overall 7,763 13.5 8 6.1 1,485 18.4 9,256 39.3
Non-DM, non-diabetes; T1DM, type 1 diabetes; T2DM, type 2 diabetes; PKPY, per thousand patient years; KDIGO eGFR categories: G1, normal or high (�90 ml/min/
1.73m2); G2, mildly decreased (�60 and <90 ml/min/1.73m2); G3a, mildly to moderately decreased (�45 and <60 ml/min/1.73m2); G3b, moderately to severely
decreased (�30 and <45 ml/min/1.73m2); G4, severely decreased (�15 and <30 ml/min/1.73m2); G5, kidney failure (<15 ml/min/1.73m2); proteinuria categories:
proteinuria categories: A1, normal to mildly increased; A2, moderately increased; A3, severely increased; A2/3, increased.
https://doi.org/10.1371/journal.pone.0221044.t002
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cohorts. A similar pattern was evident when models were applied adjusting for the interaction
between eGFR and proteinuria in the overall, merged cohort: the highest risks of progression
to MACE were associated with the more severe combinations of eGFR and proteinuria cate-
gory. This finding resembles those of a meta-analysis by Fox and colleagues,[28] in which
increasingly severe combinations of decreased kidney function and higher proteinuria were
associated with an increased risk of cardiovascular mortality in both diabetic and non-diabetic
individuals. (In our study, surprisingly, the most severe combination of all, G5/A3, was associ-
ated with only the second-highest risk of MACE, after the combination G5/A1; however, this
may have been an artefact of low numbers and consequent wide confidence intervals for the
latter combination.)
Morbidity in the kidney leads to cardiovascular morbidity, and vice versa. Thus, morbidity
in these two vital organs is closely interrelated. Disease risk in both organs is also affected by
hyperglycaemia from diabetes, although more so in the kidney. These interrelationships are
therefore complex and involve an interplay between metabolic diseases, microvascular disease,
and macrovascular disease. The complex morbid interaction is due, in all likelihood, to a clus-
tering of risk factors, including ageing, high blood pressure, and dyslipidaemia.[29] Other risk
factors may also play a part, such as anaemia, volume overload, and systemic inflammation.
Haemodynamic abnormalities can activate renal inflammation leading to fibrosis, which may
then in turn result in cardiovascular morbidity. This is exemplified by the statistic that in peo-
ple with end-stage renal disease treated with dialysis, the risk of cardiovascular mortality is
increased 10- to 20-fold compared with those without CKD.[30] Furthermore, angiotensin-
converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) commonly
used to for renoprotection and in the management of hypertension and heart failure have
complex effects on renal function via the renin–angiotensin system. All these factors, and oth-
ers, have an impact on the patterns of association that we report. Nevertheless, these general
patterns of association appear to be both clear and predictable and demonstrate an unmet
need to reduce cardiovascular risk in all people with renal disease regardless of their diabetes
status.
Where people have type 2 diabetes, some of the newer antidiabetes drugs, the SGLT2 inhib-
itors and GLP-1 receptor agonists, have demonstrated cardiovascular benefit and well as some
benefits on renal outcomes.[31] Taken together, the results from this study suggest that may
be a place for these and other therapies in the management of diabetics with renal disease
given their excess risk of cardiovascular outcomes.
There are strengths and limitations that can be drawn from the study design and data
source. Routine observational data have the merit of including large numbers of people in a
real-world setting. However, both eGFR and proteinuria measurements could be taken at any
time, and observations are therefore sometimes understandably sparse and lacking in struc-
ture, which may introduce variability. Proteinuria was not measured in a standard way, and
therefore we had to distil the various methods of recording into broad categories, creating a
new category (A2/3) where the extent of proteinuria increase was not known. Patients with no
proteinuria measurements in our data progressed more rapidly to MACE than did patients
with known proteinuria status, and this may be because patients in the former group had
more advanced renal morbidity and were being predominantly monitored in secondary care,
the test data from which are not included in our data source. We may have identified people
with diabetes whose kidney disease had a non-diabetic aetiology. We did not adjust for antihy-
pertensive or antidiabetic medication in our analyses. There were low numbers of people in
the type 1 diabetes cohort and also in the G5 category, and findings from the G5 category in
particular need to be interpreted with caution. Although used commonly, MACE is a compos-
ite clinical endpoint that includes both cardiovascular and cerebrovascular disease events.
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Conclusions
This population-based study demonstrated that the risk of MACE increased with increasing
disease severity within non-diabetes and type 2 diabetes cohorts in relation to renal morbidity
as measured by eGFR and proteinuria. These two metrics were independent risk markers.
The observation that reduced eGFR and increased proteinuria appear synergistic with
respect to risk of ischaemic cardiovascular events is of significant concern. Treatment intensifi-
cation to achieve control of hypertension by means of agents such as ACE inhibitors and spiro-
nolactone that act via the renin–angiotensin system is clearly warranted both to preserve renal
function and reduce protein loss.
We have also demonstrated that individuals with type 2 diabetes have a much higher risk of
MACE than those without diabetes after accounting for eGFR level. Intensified glycaemic con-
trol with agents that are known to reduce the risk of cardiovascular events but not significantly
increase the risk of hypoglycaemia, (such as SGLT-2 inhibitors and GLP-1 receptor agonists)
may also be important with respect to preserving renal function.
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